TOBRASONE Drug Patent Profile

When do Tobrasone patents expire, and when can generic versions of Tobrasone launch?

Tobrasone is a drug marketed by Harrow Eye and is included in one NDA.

The generic ingredient in TOBRASONE is fluorometholone acetate; tobramycin. There are five drug master file entries for this compound. Additional details are available on the fluorometholone acetate; tobramycin profile page.

Summary for TOBRASONE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	65
DailyMed Link:	TOBRASONE at DailyMed

US Patents and Regulatory Information for TOBRASONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	TOBRASONE	fluorometholone acetate; tobramycin	SUSPENSION/DROPS;OPHTHALMIC	050628-001	Jul 21, 1989		DISCN	No	No

Expired US Patents for TOBRASONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harrow Eye	TOBRASONE	fluorometholone acetate; tobramycin	SUSPENSION/DROPS;OPHTHALMIC	050628-001	Jul 21, 1989

International Patents for TOBRASONE

See the table below for patents covering TOBRASONE around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	9203503	COMBINACION DE LA TOBRAMICINA Y LA DEXAMETASONA PARA USO OFTALMICO TOPICO.
South Korea	960009262
Japan	H08231405	COMBINATION OF TOBRAMYCIN AND STEROID FOR LOCAL OPHTHALMOLOGICAL APPLICATION
Japan	H02503439
Denmark	561989
Canada	1338554	COMBINATION DE TOBRAMYCINE ET DE STEROIDES POUR APPLICATIONS OPHTALMOLOGIQUES TOPIQUES (COMBINATION OF TOBRAMYCIN AND STEROIDS FOR TOPICAL OPHTHALMIC USE)

TOBRASONE Market Analysis and Financial Projection Experimental

Tobramycin Eye Drops Market Dynamics and Financial Trajectory

Introduction

Tobramycin eye drops, a potent antibiotic used to treat bacterial eye infections, are experiencing significant growth in the global market. This article delves into the market dynamics, financial trajectory, and key factors influencing the tobramycin eye drops market.

Market Size and Growth

The global tobramycin eye drop market is projected to witness substantial growth over the coming years. As of 2023, the market was valued at approximately $0.76 billion and is expected to reach $0.86 billion in 2024, with a compound annual growth rate (CAGR) of 12.3%[1][4].

By 2028, the market is anticipated to expand to $1.37 billion, maintaining a CAGR of 12.4%[1]. By 2031, the market is estimated to reach $2,573.2 million, exhibiting a CAGR of 14.1% from 2024 to 2031[4].

Regional Market Performance

North America dominated the tobramycin eye drop market in 2023, but the Asia-Pacific region is expected to be the fastest-growing segment during the forecast period. This growth is driven by expanding healthcare infrastructure and increasing adoption of tobramycin eye drops among ophthalmologists in these regions[1].

Market Drivers

Rising Incidence of Eye Infections

The increasing prevalence of eye infections, particularly bacterial keratitis, is a significant driver of the market. As the number of eye infections rises globally, the demand for effective treatments like tobramycin eye drops also increases[4].

Growing Number of Ophthalmic Surgeries

The rise in the number of cataract and refractive surgeries contributes to the market growth. These surgeries often require antibiotic eye drops to prevent post-operative infections, further boosting the demand for tobramycin eye drops[4].

Expanding Healthcare Infrastructure

Advancements in healthcare infrastructure, especially in emerging markets, are facilitating better access to ophthalmic care and treatments. This expansion is crucial for the growth of the tobramycin eye drop market[1].

Increasing Online Availability

The growing number of e-commerce websites offering tobramycin eye drops has made these products more accessible to a wider audience. This increased availability, coupled with growing awareness about eye care, is providing opportunities for market growth[4].

Market Restraints

Side Effects and Alternative Treatments

Despite the market's positive outlook, there are several restraints. Long-term use of tobramycin eye drops can lead to side effects, which may deter some patients. Additionally, the development of alternative treatment options could potentially hinder market growth during the forecast period[4].

Clinical and Regulatory Landscape

Approvals and Clinical Trials

The market is driven by increasing approvals for tobramycin eye drops and positive outcomes from clinical trials. These approvals and favorable trial results enhance the credibility and adoption of these eye drops among healthcare professionals[1].

Regulatory Environment

The regulatory environment plays a crucial role in the market's growth. For instance, the period of marketing exclusivity for breakthrough drugs has decreased over time, allowing for quicker entry of follow-on drugs into the market. This trend suggests that the pharmaceutical industry is becoming more competitive, which can benefit the tobramycin eye drop market[3].

Competitive Landscape

Follow-On Drugs and Market Competition

The development of follow-on or 'me-too' drugs is a common practice in the pharmaceutical industry. These drugs often provide additional therapeutic options and can inject price competition into the market. The study on the economics of follow-on drug research and development indicates that the distinctions between breakthrough and 'me-too' drugs may not be very meaningful, as development races rather than post hoc imitation characterize new drug development[3].

Emerging Markets and Opportunities

Expansion into Emerging Markets

The expansion of tobramycin eye drops into emerging markets is a significant opportunity for growth. As these markets develop their healthcare infrastructure, the demand for effective ophthalmic treatments is expected to increase[1].

Consumer Awareness and Education

Growing Awareness of Eye Care

Increasing awareness about eye care and the importance of treating bacterial eye infections effectively is driving the market. Educational campaigns and healthcare initiatives aimed at promoting eye health are contributing to the growing demand for tobramycin eye drops[4].

Financial Projections

Revenue Growth

The financial trajectory of the tobramycin eye drop market is promising, with projected revenues increasing from $0.76 billion in 2023 to $2,573.2 million by 2031. This growth is supported by the increasing adoption of these eye drops, expanding healthcare infrastructure, and rising incidence of eye infections[1][4].

Key Takeaways

• The global tobramycin eye drop market is expected to grow significantly, driven by increasing eye infections, expanding healthcare infrastructure, and growing online availability.
• North America currently dominates the market, but the Asia-Pacific region is expected to be the fastest-growing segment.
• Side effects and the development of alternative treatments are potential restraints to market growth.
• The market is influenced by regulatory changes, clinical trial outcomes, and the competitive landscape of follow-on drugs.

FAQs

Q: What is the current market size of the tobramycin eye drop market? A: As of 2023, the global tobramycin eye drop market was valued at approximately $0.76 billion[1].

Q: What is the projected CAGR for the tobramycin eye drop market from 2024 to 2031? A: The market is expected to exhibit a CAGR of 14.1% from 2024 to 2031[4].

Q: Which region is expected to be the fastest-growing segment for tobramycin eye drops? A: The Asia-Pacific region is anticipated to be the fastest-growing segment during the forecast period[1].

Q: What are the main drivers of the tobramycin eye drop market? A: The main drivers include the rising incidence of eye infections, growing number of ophthalmic surgeries, expanding healthcare infrastructure, and increasing online availability[4].

Q: What are the potential restraints to the growth of the tobramycin eye drop market? A: Side effects associated with long-term use and the development of alternative treatment options are potential restraints[4].

Sources

1. Tobramycin Eye Drops Market Segments, Drivers, Restraints, And Trends For 2024-2033 - EIN Presswire
2. Anteproyectos de regulación y Manifiestos de Impacto Regulatorio - Proyectoscemer
3. The economics of follow-on drug research and development - PubMed
4. Global Tobramycin Eye Drop Market Size and Trends - Coherent Market Insights
5. Hope Star Newspaper Archives, Jan 28, 1936, p. 2 - NewspaperArchive.com